| 0.157 0 (0%) | 03-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.51 | 1-year : | 0.6 |
| Resists | First : | 0.44 | Second : | 0.51 |
| Pivot price | 0.33  |
|||
| Supports | First : | 0.27 |
Second : | 0.18 |
| MAs | MA(5) : | 0.32 |
MA(20) : | 0.34 |
| MA(100) : | 0.33 |
MA(250) : | 0.49 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 37 |
D(3) : | 34 |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 0.83 | Low : | 0.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MDNA ] has closed above bottom band by 43.2%. Bollinger Bands are 43.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.34 - 0.34 | 0.34 - 0.34 |
| Low: | 0.31 - 0.31 | 0.31 - 0.31 |
| Close: | 0.33 - 0.33 | 0.33 - 0.33 |
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Thu, 15 Feb 2024
MDNA is undervalued, Research Capital says - Cantech Letter
Mon, 20 Nov 2023
MDNA.TO: Overall Survival Data from Phase 2b Trial of Bizaxofusp Presented at SNO 2023… - Yahoo Finance
Mon, 30 Oct 2023
Why Is Medicenna Therapeutics (MDNA) Stock Down Today? - InvestorPlace
Fri, 27 Oct 2023
MDNA stock hammered on Nasdaq delisting - Cantech Letter
Thu, 06 Jul 2023
MDNA: Full MDNA11 Clinical Update in Calendar 3Q23… - Yahoo Finance
Wed, 19 Apr 2023
MDNA: Update on ABILITY Trial… - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 70 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 23.6 (%) |
| Held by Institutions | 13.5 (%) |
| Shares Short | 109 (K) |
| Shares Short P.Month | 278 (K) |
| EPS | -0.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.8 % |
| Return on Equity (ttm) | -39 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -3.67 |
| PEG Ratio | 0 |
| Price to Book value | 0.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|